HHS Proposes Label Changes for Testosterone Replacement Therapies

The U.S. Department of Health and Human Services is seeking comprehensive updates to the prescribing information for testosterone replacement therapy products. These proposed revisions aim to align product labels with current clinical evidence, including removing a previous usage limitation for age-related hypogonadism. Additionally, warnings regarding prostate cancer and benign prostatic hyperplasia would be adjusted.